Center for Cancer Immunotherapy

Center for Cancer Immunotherapy

The Center for Cancer Immunotherapy at La Jolla Institute is at the forefront of exploring new and sometimes unexpected avenues for novel immune-based cancer treatments, as well as predicting and improving the effectiveness of existing immunotherapies. It brings together some of the world’s most innovative scientists, who are not afraid to leave the beaten path and tackle major questions in new ways: How to select the best targets for personalized cancer vaccines? How to predict which patients will respond to cancer immunotherapy and how to overcome tumor resistance? How to engage hitherto ignored types of immune cells in the fight against cancer?


Cancer immunotherapies rally a patient’s immune cells to attack tumor cells and are a source of great hope in cancer care. Several of them are specifically designed to supercharge T cells, which use receptors on their surface to scan anything they encounter to determine whether it is friend or foe. These game-changing treatments have brought cancer patients back from the brink and vanquished tumors resistant to conventional therapies. Despite being hailed as miracle cures, immune-based cancer therapies actually only benefit a minority of cancer patients. The problem is that tumors have developed a suite of molecular tools to thwart the ability of T cells to recognize and kill cancer cells. This challenge has prompted our scientists to look to different divisions of the immune system to overcome tumor cell defenses.

The Center for Cancer Immunotherapy aims to harness and amplify the cancer-fighting potential of a wide variety of immune cells to dramatically increase the number of cancer patients who benefit from cancer immunotherapy.


Amnon Altman, Ph.D.
Ferhat Ay, Ph.D.
Hilde Cheroutre, Ph.D.
Catherine “Lynn” Hedrick, Ph.D.
Patrick Hogan, Ph.D.
Bjoern Peters, Ph.D.
Anjana Rao, Ph.D.
Stephen Schoenberger, Ph.D.
Sonia Sharma, Ph.D.
Pandurangan Vijayanand, M.D. Ph.D.

From The Lab

Aug 18, 2020 // Cell

LJI team gets first-ever look at a rare but vital stem cell in humans

New understanding of immune cell origins may offer cancer and COVID-19 drug targets
Jun 17, 2020 // Nature Immunology

LJI Scientists Investigate a Powerful Protein Behind Antibody Development

The new study shows how a protein works as a “master regulator” in the immune system
Dec 2, 2019

LJI researchers reveal unexpected versatility of an ancient DNA repair factor

Based on its history, HMCES could be the most important protein you've never heard of
Sep 3, 2019 // UT San Diego

UCSD’s cancer vaccine trial shows range of results at the one-year mark

Jul 29, 2019 // Proceedings of the National Academy of Sciences

TET proteins: double agents in DNA methylation prevent catastrophic cancer